Geron Co. (NASDAQ:GERN) saw a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 27,550,000 shares, a decrease of 23.4% from the March 15th total of 35,950,000 shares. Based on an average daily trading volume, of 3,830,000 shares, the short-interest ratio is currently 7.2 days.
Shares of GERN traded down $0.08 during mid-day trading on Monday, reaching $1.39. The company’s stock had a trading volume of 78,654 shares, compared to its average volume of 3,670,003. The company has a debt-to-equity ratio of 0.10, a current ratio of 9.60 and a quick ratio of 9.60. Geron has a 12-month low of $1.10 and a 12-month high of $2.40. The company’s 50 day moving average is $1.68 and its 200 day moving average is $1.78. The stock has a market cap of $442.76 million, a PE ratio of -3.97 and a beta of 1.50.
Geron (NASDAQ:GERN) last posted its quarterly earnings data on Wednesday, March 10th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.01). Geron had a negative net margin of 21,631.02% and a negative return on equity of 43.76%. The company had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.08 million. During the same period in the prior year, the company earned ($0.15) earnings per share. As a group, sell-side analysts anticipate that Geron will post -0.27 EPS for the current fiscal year.
A number of research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating on shares of Geron in a report on Thursday, April 8th. Zacks Investment Research downgraded Geron from a “hold” rating to a “sell” rating in a research report on Monday, February 22nd. Finally, B. Riley reiterated a “buy” rating on shares of Geron in a research note on Wednesday, February 17th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $3.83.
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Further Reading: Why do companies issue stock splits?
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.